{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Therapy&page=4", "query": { "condition": "First Line Therapy", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 1005, "total_pages": 101, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Therapy&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=First+Line+Therapy&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T18:18:54.091Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00603941", "title": "A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Anaplastic Thyroid Cancer" ], "interventions": [ { "name": "CS-7017", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2008-01", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2020-09-16", "last_synced_at": "2026-10-20T18:18:54.091Z", "location_count": 10, "location_summary": "Aurora, Colorado • Jacksonville, Florida • Boston, Massachusetts + 7 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00603941" }, { "nct_id": "NCT00226005", "title": "PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neoplasm" ], "interventions": [ { "name": "PTK787/ZK222584", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pancreatic Cancer Research Team", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 67, "start_date": "2005-12", "completion_date": "2010-02", "has_results": false, "last_update_posted_date": "2012-05-09", "last_synced_at": "2026-10-20T18:18:54.091Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Beverly Hills, California + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00226005" }, { "nct_id": "NCT03783442", "title": "A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Esophageal Squamous Cell Carcinoma (ESCC)" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Fluorouracil (5-FU)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "BeiGene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 649, "start_date": "2018-12-11", "completion_date": "2024-08-22", "has_results": true, "last_update_posted_date": "2025-07-29", "last_synced_at": "2026-10-20T18:18:54.091Z", "location_count": 2, "location_summary": "New Haven, Connecticut • The Woodlands, Texas", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "The Woodlands", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03783442" }, { "nct_id": "NCT00998166", "title": "A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Columbia University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2009-06", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2024-07-30", "last_synced_at": "2026-10-20T18:18:54.091Z", "location_count": 2, "location_summary": "Lake Success, New York • New York, New York", "locations": [ { "city": "Lake Success", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00998166" }, { "nct_id": "NCT00000975", "title": "A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Histoplasmosis" ], "interventions": [ { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 30, "start_date": null, "completion_date": "1994-09", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-10-20T18:18:54.091Z", "location_count": 12, "location_summary": "Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000975" }, { "nct_id": "NCT03581357", "title": "Mobile Mindfulness Meditation Intervention to Improve the Well-Being of Cancer Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cancer, Other Than Non-melanoma Skin Cancer" ], "interventions": [ { "name": "Mobile Mindfulness Meditation", "type": "BEHAVIORAL" }, { "name": "Mindfulness Coach", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Hawaii", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 302, "start_date": "2019-04-03", "completion_date": "2023-07-11", "has_results": false, "last_update_posted_date": "2023-08-24", "last_synced_at": "2026-10-20T18:18:54.091Z", "location_count": 2, "location_summary": "Palo Alto, California • Honolulu, Hawaii", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" } ], "official_url": "https://clinicaltrials.gov/study/NCT03581357" }, { "nct_id": "NCT06801067", "title": "A Study of SER-155 to Treat Diarrhea in People on Immunotherapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diarrhea", "Enterocolitis" ], "interventions": [ { "name": "SER-155", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2025-01-24", "completion_date": "2027-01-24", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-10-20T18:18:54.091Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06801067" }, { "nct_id": "NCT07091019", "title": "A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myelogenous Leukemia - Chronic Phase" ], "interventions": [ { "name": "TKIs", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 1000, "start_date": "2025-12-17", "completion_date": "2033-04-20", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-20T18:18:54.091Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Stockton, California • Torrance, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Stockton", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Stamford", "state": "Connecticut" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07091019" }, { "nct_id": "NCT01881230", "title": "Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Breast Tumor", "Breast Cancer", "Cancer of the Breast", "Estrogen Receptor- Negative Breast Cancer", "HER2- Negative Breast Cancer", "Progesterone Receptor- Negative Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer", "Triple-negative Breast Cancer", "Triple-negative Metastatic Breast Cancer", "Metastatic Breast Cancer" ], "interventions": [ { "name": "nab-Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 191, "start_date": "2013-09-26", "completion_date": "2016-10-28", "has_results": true, "last_update_posted_date": "2019-02-21", "last_synced_at": "2026-10-20T18:18:54.091Z", "location_count": 64, "location_summary": "Chandler, Arizona • Glendale, Arizona • Scottsdale, Arizona + 57 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fayetteville", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01881230" }, { "nct_id": "NCT06948448", "title": "A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "ONO-4578", "type": "DRUG" }, { "name": "Opdivo®", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ono Pharmaceutical Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2025-11-18", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-20T18:18:54.091Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Los Angeles, California • Lone Tree, Colorado + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06948448" } ] }